Skip to main content
    S

    Standard Biotools Inc (LAB)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $0.54
    -0.08 (-13.14%)

    Market Cap: $279.27M

    Last updated: Nov 17, 2026 at 4:32 PM ET

    Standard Biotools Inc (LAB) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Standard Biotools (LAB) has a market cap of $279.27M and an enterprise value of $12.09M. It kept 208.40% of revenue as net income over the last 12 months. It holds $267.19M more cash than debt, 95.67% of its market cap.

    Total Valuation

    Enterprise value is 95.67% below the market cap, as cash exceeds debt.

    Market Cap$279.27M
    Enterprise Value$12.09M
    Latest price (Nov 17, 2026)$0.54

    Key Dates

    Last Earnings DateNov 3, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.68% in the quarter ended Sep 30, 2026 and grew 2.92% a year over 2 years.

    Shares Outstanding393.56M
    Shares Change (YoY)+2.86%
    Shares Change (QoQ)+0.68%
    Share Count Growth (2Y CAGR)+2.92%

    Valuation Ratios

    Sales and book value multiples are 3.3x and 0.4x. Its year-end P/S ranged from 0.9x to 7.5x from 2022 to 2025.

    P/S Ratio3.3x
    P/B Ratio0.4x

    Valuation history and multiples

    Price Statistics

    The stock is down 56.50% over 52 weeks and trades 19.40% below its 50-day average.

    Beta (1Y)1.17
    52-Week Change-56.50%
    1-Month Change-16.15%
    3-Month Change-19.68%
    6-Month Change-46.06%
    Total Return (1Y)-56.50%
    Total Return (3Y CAGR)-37.78%
    Max Drawdown (1Y)-67.89%
    Max Drawdown (3Y)-81.53%
    Sharpe Ratio (1Y)-1.15
    Correlation with SPY (1Y)0.22
    50-Day Average$0.67
    200-Day Average$0.86
    52-Week Range$0.59 to $1.72
    RSI (14 Days)35.8
    Average Volume (20 Days)1.03M

    Price chart

    Financial Position

    Current assets cover 9.75x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio9.75x
    Quick Ratio9.40x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on invested capital is -9.94% over the last 12 months, against a 5-year average of 293.38%.

    Return on Equity (ROE)23.95%
    Return on Assets (ROA)20.95%
    Return on Invested Capital (ROIC)-9.94%
    ROA (5Y Average)-25.84%
    ROIC (5Y Average)293.38%
    Asset Turnover0.11x
    Inventory Turnover1.64x
    Receivables Turnover4.45x
    Cash Conversion Cycle221 days

    Scores

    LAB has an Altman Z-Score of -0.42, in the distress zone below 1.81, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.

    Altman Z-Score-0.42
    Altman Z ZoneDistress
    Piotroski F-Score4 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $63.86M over the last 12 months is up 2.29% from the 12 months before.

    Revenue$63.86M
    Revenue Growth (YoY)+2.29%
    Gross Profit$35.36M
    Operating Income-$76.30M
    Pretax Income-$70.34M
    Net Income$133.08M
    Reported EPS (TTM)-$0.06

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 87.47% of the $635.33M in total assets.

    Cash and Equivalents$267.49M
    Total Debt$300.00K
    Net Cash$267.19M
    Net Cash Per Share$0.68
    Working Capital$446.28M
    Shareholder Equity$555.75M
    Book Value Per Share$1.41
    Total Assets$635.33M
    Total Liabilities$79.58M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$64.26M
    FCF Per Share-$0.17
    Depreciation and Amortization$8.68M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -119.48%.

    Gross Margin55.38%
    Operating Margin-119.48%
    Pretax Margin-110.15%
    Net Margin208.40%
    Gross Margin (5Y Average)47.51%

    Growth

    Revenue fell 4.49% a year over 3 years.

    Revenue Growth (3Y CAGR)-4.49%
    Revenue Growth (5Y CAGR)-9.19%

    Revenue and profit by year

    Dividends and Yields

    LAB does not pay a dividend.

    Buyback Yield-0.16%
    Shareholder Yield-0.16%

    Peer Position

    Against 12 similar companies, LAB has the 5th highest P/S.

    P/S Ratio3.3x vs 2.3x median
    ROIC-9.94% vs -26.15% median
    Revenue Growth (Trailing 4 Quarters, YoY)+2.29% vs +13.78% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at -1.91% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)-1.91%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About LAB

    What is LAB's market cap?

    Standard Biotools has a market cap of $279.27M. Its enterprise value, which adds debt and subtracts cash, is $12.09M.

    How many shares of LAB are outstanding?

    Standard Biotools has 393.56M shares outstanding. The count is up 2.86% from a year earlier.

    Does LAB pay a dividend?

    No. Standard Biotools does not pay a dividend.

    How much debt does LAB have?

    Standard Biotools has $300.00K of total debt and $267.49M of cash and equivalents, a net cash position of $267.19M.